Nanoscope Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
47
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.5M
- Investors
-
4
Nanoscope Therapeutics General Information
Description
Developer of a therapeutic gene and delivery platform designed to be used for vision restoration. The company is developing optogenetic gene therapies using multi-characteristic opsin to re-sensitize the retina in order to detect low light levels, enabling patients to recover from diseases like dry and age-related macular degeneration.
Contact Information
Website
www.nanostherapeutics.comCorporate Office
- Trinity Towers
- 2777 North Stemmons Freeway
- Dallas, TX 75207
- United States
Corporate Office
- Trinity Towers
- 2777 North Stemmons Freeway
- Dallas, TX 75207
- United States
Nanoscope Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 14-Sep-2021 | $1.5M | Completed | Clinical Trials - Phase 3 | ||
| 2. Early Stage VC (Series A) | 21-Jul-2020 | Completed | Clinical Trials - Phase 3 | |||
| 1. Grant | 28-May-2020 | $2M | Completed | Clinical Trials - Phase 3 |
Nanoscope Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Nanoscope Therapeutics Patents
Nanoscope Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4704877-A2 | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | Pending | 24-Apr-2023 | ||
| US-20260295090-A1 | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | Pending | 24-Apr-2023 | ||
| WO-2024226667-A2 | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | Inactive | 24-Apr-2023 | ||
| WO-2024226667-A3 | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | Inactive | 24-Apr-2023 | ||
| US-12459977-B2 | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | Active | 06-Nov-2016 | C07K14/47 |
Nanoscope Therapeutics Signals
Nanoscope Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AG Collective Capital | Venture Capital | Minority | ||
| CKG Management | Venture Capital | Minority | ||
| National Eye Institute | Government | |||
| U.S. Department of Health and Human Services | Government |
Nanoscope Therapeutics FAQs
-
When was Nanoscope Therapeutics founded?
Nanoscope Therapeutics was founded in 2017.
-
Where is Nanoscope Therapeutics headquartered?
Nanoscope Therapeutics is headquartered in Dallas, TX.
-
What is the size of Nanoscope Therapeutics?
Nanoscope Therapeutics has 47 total employees.
-
What industry is Nanoscope Therapeutics in?
Nanoscope Therapeutics’s primary industry is Drug Discovery.
-
Is Nanoscope Therapeutics a private or public company?
Nanoscope Therapeutics is a Private company.
-
What is Nanoscope Therapeutics’s current revenue?
The current revenue for Nanoscope Therapeutics is .
-
How much funding has Nanoscope Therapeutics raised over time?
Nanoscope Therapeutics has raised $12.8M.
-
Who are Nanoscope Therapeutics’s investors?
AG Collective Capital, CKG Management, National Eye Institute, and U.S. Department of Health and Human Services have invested in Nanoscope Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process